Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies

2018; Elsevier BV; Volume: 132; Issue: 13 Linguagem: Inglês

10.1182/blood-2018-01-828277

ISSN

1528-0020

Autores

Carl E. Allen, Rebecca Marsh, Peter Dawson, Catherine M. Bollard, Shalini Shenoy, Philip Roehrs, Rabi Hanna, Lauri M. Burroughs, Leslie S. Kean, Julie‐An Talano, Kirk R. Schultz, Sung‐Yun Pai, K. Scott Baker, Jeffrey R. Andolina, Elizabeth Stenger, James A. Connelly, Alyssa Ramirez, Christopher Bryant, Mary Eapen, Michael A. Pulsipher,

Tópico(s)

Immune Cell Function and Interaction

Resumo

Key Points A prospective reduced-intensity HCT trial for HLH/primary immunodeficiency resulted in low early mortality and 1-year OS of 80%. Conditioning with fludarabine, melphalan, and alemtuzumab was associated with high rates of mixed chimerism and graft failure.

Referência(s)